Get the Stockscreener App
9.21
0.77%
0.07
After Hours:
9.21
Evolus Inc stock is traded at $9.21, with a volume of 796.10K.
It is up +0.77% in the last 24 hours and up +0.22% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$9.14
Open:
$9.13
24h Volume:
796.10K
Relative Volume:
0.79
Market Cap:
$636.37M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-8.5278
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-1.81%
1M Performance:
+0.22%
6M Performance:
-16.58%
1Y Performance:
-15.12%
1-Day Range:
$9.07
$9.375
1-Week Range:
$9.00
$9.6799
52-Week Range:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.21 | 636.37M | 202.09M | -61.69M | -35.64M | -1.08 |
|
RGC
Regencell Bioscience Holdings Ltd
|
17.04 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.95 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.37 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.46 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 - BioSpace
(EOLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Midday Stock Roundup: Xponential Fitness Down, Yoshiharu Up - Orange County Business Journal
Evolus Inc (EOLS) Stock Price Up 3.95% on Jun 11 - GuruFocus
Insider Spends US$189k Buying More Shares In Evolus - simplywall.st
Insider Buying: White Albert G III Acquires 20,000 Shares of Evolus Inc (EOLS) - GuruFocus
EOLS Director Boosts Stake with Significant Share Purchase | EOLS Stock News - GuruFocus
Evolysse™ Recognized in 2025 Shape Skin Awards | EOLS Stock News - GuruFocus
Evolysse™ Recognized in 2025 Shape Skin Awards - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Holdings Lowered by Squarepoint Ops LLC - Defense World
Evolus Announces Board Changes and Director Elections - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: A 142% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Bank of America Corp DE - Defense World
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EO - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Shares Bought by Ameriprise Financial Inc. - Defense World
EOLS Set to Participate in BTIG's Virtual Meeting on June 9 | EOLS Stock News - GuruFocus
Evolus Launches Second Product Line for Wrinkles - Orange County Business Journal
ProShare Advisors LLC Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $347,000 Stock Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus announces CFO resignation - MSN
Stifel maintains Evolus stock buy rating, $25 target - Investing.com Australia
Stifel maintains Evolus stock buy rating, $25 target By Investing.com - Investing.com Nigeria
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS) - simplywall.st
Mizuho maintains Evolus stock Outperform rating and $25 target By Investing.com - Investing.com India
Evolus CFO Sandra Beaver resigns for new role By Investing.com - Investing.com South Africa
Mizuho maintains Evolus stock Outperform rating and $25 target - Investing.com
Evolus CFO to Resign - Orange County Business Journal
Evolus CFO Sandra Beaver Resigns - MarketScreener
Evolus (EOLS) CFO Resignation Announced - GuruFocus
Evolus CFO Sandra Beaver resigns for new role - Investing.com India
Evolus CFO Sandra Beaver Announces Resignation - TipRanks
Resignation of CFO Impacts Evolus (EOLS) Leadership | EOLS Stock News - GuruFocus
Evolus Announces Departure of its Chief Financial Officer | EOLS Stock News - GuruFocus
Evolus announces departure of CFO Sandra Beaver - TipRanks
Evolus Announces Departure Of Its Chief Financial Officer - marketscreener.com
Evolus Announces Departure of its Chief Financial Officer - Business Wire
BNP Paribas Financial Markets Has $400,000 Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolysse HA gels outperform Restylane in clinical study - Investing.com Australia
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels - marketscreener.com
Evolus announces publication of U.S. pivotal study for Evolysse injectable gels - TipRanks
EOLS Publishes Promising Study Results on Evolysse Injectable Gels | EOLS Stock News - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - BioSpace
Evolysse HA gels outperform Restylane in clinical study By Investing.com - Investing.com Canada
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels | EOLS Stock News - GuruFocus
Trend Tracker for (EOLS) - news.stocktradersdaily.com
Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Comerica Bank Purchases New Stake in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
0.07%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):